Sep 27, 2023 / 03:30PM GMT
Charles Cliff Duncan - Cantor Fitzgerald & Co., Research Division - Research Analyst
It's been around for a while, and I've admired for a long time. However, I only recently had an opportunity to pick up coverage of Alkermes, and I'm excited to do so. Frankly, I think that this is long been a neuro innovator that has been overlooked and it is becoming increasingly a more -- a company more focused on neuro innovation and developing a pipeline drugs -- pipeline of drugs meant to treat a range of neurological and psychiatric disorders. And in addition, it has a strong commercial base. So with me today is Blair Jackson, the company's Chief Operating Officer. Blair, welcome. Good to see you.
Blair C. Jackson - Alkermes plc - Executive VP & COO
Nice to see you as well.
Questions and Answers:
Charles Cliff Duncan - Cantor Fitzgerald & Co., Research Division - Research AnalystThanks for joining. I think Blair we'll start probably with an overview and -- I like your socks, I'm a cyclist as well. And then we
Trustpilot
